Ra Capital Management, L.P. - Jul 21, 2023 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol
ABOS
Transactions as of
Jul 21, 2023
Transactions value $
$39,999,998
Form type
4
Date filed
7/25/2023, 04:30 PM
Previous filing
Jul 21, 2023
Next filing
Aug 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Purchase $40M +5.16M +65.48% $7.75 13M Jul 21, 2023 See Footnotes F1, F2, F3
holding ABOS Common Stock 1.3M Jul 21, 2023 See Footnotes F3, F4
holding ABOS Common Stock 589K Jul 21, 2023 See Footnotes F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on July 20, 2023.
F2 Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4 Held directly by the Nexus Fund II.
F5 Held directly by the Account.

Remarks:

Ms. Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors.